PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 214 filers reported holding PDL BIOPHARMA INC in Q1 2015. The put-call ratio across all filers is 0.29 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $1,000 | 0.0% | 300 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $1,000 | 0.0% | 300 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $1,000 | 0.0% | 300 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $1,000 | 0.0% | 300 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $1,000 | 0.0% | 300 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $1,000 | 0.0% | 300 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $1,000 | 0.0% | 300 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $1,000 | 0.0% | 300 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $1,000 | -50.0% | 300 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $2,000 | 0.0% | 300 | 0.0% | 0.00% | 0.0% |
| Q2 2015 | $2,000 | 0.0% | 300 | 0.0% | 0.00% | 0.0% |
| Q1 2015 | $2,000 | 0.0% | 300 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $2,000 | 0.0% | 300 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $2,000 | -50.0% | 300 | -40.0% | 0.00% | -66.7% |
| Q2 2014 | $4,000 | 0.0% | 500 | 0.0% | 0.00% | 0.0% |
| Q1 2014 | $4,000 | 0.0% | 500 | 0.0% | 0.00% | 0.0% |
| Q4 2013 | $4,000 | – | 500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 2,632,000 | $8,817,000 | 2.83% |
| AMERICAFIRST CAPITAL MANAGEMENT, LLC | 551,804 | $1,848,543,000 | 1.54% |
| Nine Chapters Capital Management LLC | 24,300 | $81,000 | 0.57% |
| GREAT POINT PARTNERS LLC | 645,000 | $2,161,000 | 0.55% |
| Virtus ETF Advisers LLC | 198,901 | $666,000 | 0.32% |
| GSA CAPITAL PARTNERS LLP | 1,521,224 | $5,096,000 | 0.27% |
| Amici Capital, LLC | 200,000 | $670,000 | 0.18% |
| Acrospire Investment Management LLC | 70,622 | $237,000 | 0.16% |
| RBF Capital, LLC | 273,976 | $918,000 | 0.16% |
| SECOR Capital Advisors, LP | 383,971 | $1,286,000 | 0.14% |